ClinicalTrials.gg
CompletedNCT05940597FACIL AFUpdated Oct 26, 2026

Pulsed Field Ablation vs Cryoablation In Paroxysmal Atrial Fibrillation

An interventional study of Pulse field ablation and Cryoballoon pulmonary vein isolation in Atrial Fibrillation Paroxysmal, sponsored by University Hospital, Grenoble. Completed at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now CompletedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in Atrial Fibrillation with a site in France — 63 open to participants now, 87 under way, 5 of them phase 3. Atrial Fibrillation · France.

Enrollment
73rd of 193
354 · median 250
Started
2023
with 21 others
No phase
117 of 317
32 open now
Registered
259th of 317
by date

Among the 317 studies in Atrial Fibrillation with a site in France, this one is the 73rd largest by enrollment of the 193 interventional ones that give a count, is one of 22 that started in 2023, is one of 117 with no phase, and was the 259th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

63 of the 317 studies in Atrial Fibrillation with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in Atrial Fibrillation with a site in France, or all of them as a file.
02

Study summary

Cryoballoon pulmonary vein isolation (PVI) has emerged as an alternative to radiofrequency in the treatment of drug-resistant atrial fibrillation (AF). (1) Cryoablation offers potential advantages over radiofrequency, including shorter procedure times, decreased fluoroscopy time, shorter hospital length of stay, and different rates and types of complications. (2) The efficacy over a mean follow-up of one year with cryoablation for AF is comparable to that of radiofrequency ablation in a prospective randomized trial, with a lower major complication rate (3, 4). In recent years, AF cryoablation has established itself as a real alternative to RF ablation, to the point that this ablative source is chosen in one out of five European patients undergoing PV isolation. 70-80% of patients maintain sinus rhythm after a first procedure, showing an efficacy rate equivalent to ablation by RF. It is also comparable to RF when it comes to safety. Phrenic nerve palsy remains the major concern of cryoablation, accounting for 40% of periprocedural complications. A reduction in total procedure time and less dependence on the operator's experience make cryoablation an attractive choice for centres starting an AF ablation program. In conclusion, we do not yet have definitive data to affirm the superiority of one energy source over the other. Generally the choice depends on the availability of the centre and on the experience of the operator.

Pulse field ablation (PFA): Vivek Y. Reddy demonstrates that in patients with paroxysmal atrial fibrillation, PFA rapidly and efficiently isolates PVs with a degree of tissue selectivity and a safety profile(1).PFA can achieve a high degree of durable PV isolation with a comparable efficiency than another techniques (RF or CRYO) at one year follow-up (2) Cryoablation has been a recognised technique for the ablation of atrial fibrillation for many years, with many studies comparing the technique to radiofrequency ablation with equal results. Studies are underway to compare radiofrequency AF ablation versus PFA (BEAT-AF study). A randomized study to compare two methods of cryoablation versus PFA will be necessary to validate the non-inferiority of the technique.

03

Conditions studied

  • Atrial Fibrillation Paroxysmal

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is of legal age to participate in the study (age >18 years)
  • The patient is eligible for ablation of paroxysmal atrial fibrillation
  • The patient or legal representative is able to understand and willing to provide written to participate in the trial
  • The patient is able and willing to return for required follow-up visits and examinations

Exclusion criteria

Exclusion Criteria:

  • Previous AF ablation
  • Persistent and permanent AF
  • The patient is or allergic to oral anticoagulation
  • The patient or legal representative is enable to understand and willing to provide written to participate in the trial
  • The patient is enable and willing to return for required follow-up visits and examinations
  • Pregnant or nursing patient
  • Patient in exclusion period of another interventional study,
  • Patient under administrative or judicial supervision
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
354 participants (actual)

Study arms

  • Active comparator
    Cryoablation arm

    Market approved cryoablation system

    Device: Cryoballoon pulmonary vein isolation

  • Experimental
    PFA arm

    Market approved PFA ablation system (Farapulse - Boston Scientific system).

    Device: Pulse field ablation

Interventions

  • DevicePulse field ablation

    ablation of paroxysmal atrial fibrillation by Pulse field ablation

  • DeviceCryoballoon pulmonary vein isolation

    ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation

06

What researchers measure

Primary outcomes

  1. proportion of subjects experiencing one-year single-procedure clinical success

    successful index of AF ablation, absence of atrial arrhythmia recurrence on any type of recording (30 sec by TTM (event monitor), holters, 12-lead ECGs, rhythm strip or other diagnostic ECG documentation), absence of use of class I or III AAD.

    Time frame: 12 months

Secondary outcomes

  1. Health-related quality of life

    SF-12 questionnaire.

    Time frame: 6 and 12 months

  2. Improvement in AF-specific quality of life

    AFEQT questionnaire

    Time frame: 6 and 12 months

  3. Proportion of patients with death

    Death from any causes

    Time frame: 12 months

  4. Proportion of patients with first hospitalization for cardiovascular causes.

    First hospitalization for cardiovascular causes

    Time frame: 12 months

  5. Proportion of patients with acute complication related to the procedure

    tamponade, stroke, myocardial infarction, other

    Time frame: during the procedure or one day after

  6. Total procedure duration

    Procedure duration in minutes

    Time frame: during the procedure

  7. Total time of fluoroscopy

    Total time of fluoroscopy in minutes

    Time frame: during the procedure

  8. Proportion of patients with embolic events from arrhythmia

    Stroke

    Time frame: 12 months

  9. Long term complications related to the procedure

    phrenic palsy, pulmonary vein stenosis, pericarditis, other

    Time frame: 12 months

  10. Recurrence of atrial fibrillation

    Absence of atrial arrhythmia recurrence on any type of recording (30 sec by TTM (event monitor), holters, 12-lead ECGs, rhythm strip or other diagnostic ECG documentation), absence of use of class I or III AAD

    Time frame: 12 months

07

Study locations

7 sites
  • CHU Caen Normandie
    Caen, France
  • Chu Grenoble Alpes
    Grenoble, 38043, France
  • CHU Montpellier
    Montpellier, France
  • Aphp / Hegp
    Paris, France
  • CHU Rouen
    Rouen, France
  • Clinique Pasteur
    Toulouse, France
  • CHRU Tours
    Tours, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Mar 2026, 29 months.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 29 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2023
First posted
Jul 11, 2023
StartActual
Sep 25, 2023
Primary completionActual
Mar 23, 2026
CompletionActual
Mar 23, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 26, 2026
Sites
6 sites added
Show 6 added (6 France)
  • CHU Caen Normandie · Caen, France
  • CHU Montpellier · Montpellier, France
  • Aphp / Hegp · Paris, France
  • CHU Rouen · Rouen, France
  • Clinique Pasteur · Toulouse, France
  • CHRU Tours · Tours, France
Oct 26, 2026
Start date
Sep 1, 2023→Sep 25, 2023
Oct 26, 2026
Enrollment
350 (estimated)→354 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Active, not recruiting→Completed
    6 sites added
    Show 6 added (6 France)
    • CHU Caen Normandie · Caen, France
    • CHU Montpellier · Montpellier, France
    • Aphp / Hegp · Paris, France
    • CHU Rouen · Rouen, France
    • Clinique Pasteur · Toulouse, France
    • CHRU Tours · Tours, France
    Start date Sep 1, 2023→Sep 25, 2023
    Enrollment 350 (estimated)→354 (actual)
    + 3 other changes: index terms, responsible party and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05940597
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Sep 25, 2023
Primary completion
Mar 23, 2026
Completion
Mar 23, 2026
Last update
Oct 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion